- 99
- 265 247
Recursion
United States
Приєднався 26 чер 2019
Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale - up to millions of wet lab experiments weekly - and massive computational scale - owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.
Recursion is headquartered in Salt Lake City with offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com.
Recursion is headquartered in Salt Lake City with offices in Toronto, Montréal, London, and the San Francisco Bay Area. Learn more at www.Recursion.com.
Yoshua Bengio: How AI Is Changing Scientific Discovery in Medicine
In a presentation that was part of the ML for Drug Discovery Summer School from Valence Labs, AI pioneer Yoshua Bengio, a Turing Award-winner, computer science professor at the University of Montreal and one of our scientific advisors, shared insights into how AI has fundamentally changed drug discovery.
Thanks to our ability to run large-scale experiments, Bengio notes, we’re able to collect massive quantities of data. Our own automated wet labs perform 2.2 million experiments per week.
“The amount of data we're collecting… is just too big for human brains to deal with,” Bengio says. “And so we need machines to help us make sense of that data.”
But, he notes, “the space of potential hypotheses to explain data or the space of potential candidates that we could experiment with that could be interesting, is huge… and only a very, very tiny fraction of these are good in some sense.”
This is where machine learning and active learning comes in, Bengio notes. “We can use machine learning in particular what's called amortized inference in order to help decide where to throw darts, whether it's in the space of hypotheses or the space of candidates for experiments. We're gonna take advantage of the ability of machine learning to generalize in order to make good guesses.”
Active learning allows us to continue this process in a constant flywheel of improvement, what we at Recursion call “cycles of virtuous learning.”
Watch the full talk here: ua-cam.com/video/7Ul_jORuB8s/v-deo.html
#ai #ml #activelearning #drugdiscovery
Thanks to our ability to run large-scale experiments, Bengio notes, we’re able to collect massive quantities of data. Our own automated wet labs perform 2.2 million experiments per week.
“The amount of data we're collecting… is just too big for human brains to deal with,” Bengio says. “And so we need machines to help us make sense of that data.”
But, he notes, “the space of potential hypotheses to explain data or the space of potential candidates that we could experiment with that could be interesting, is huge… and only a very, very tiny fraction of these are good in some sense.”
This is where machine learning and active learning comes in, Bengio notes. “We can use machine learning in particular what's called amortized inference in order to help decide where to throw darts, whether it's in the space of hypotheses or the space of candidates for experiments. We're gonna take advantage of the ability of machine learning to generalize in order to make good guesses.”
Active learning allows us to continue this process in a constant flywheel of improvement, what we at Recursion call “cycles of virtuous learning.”
Watch the full talk here: ua-cam.com/video/7Ul_jORuB8s/v-deo.html
#ai #ml #activelearning #drugdiscovery
Переглядів: 426
Відео
Recursion Advances AI-Enabled Cancer Drug
Переглядів 422Місяць тому
Announcing FDA IND clearance for a Phase I/2 clinical trial of REC-1245, our first program to reach clinical studies that derived from Recursion’s AI-enabled Maps of Biology, resulting in target identification to IND enabling studies in under 18 months (more than twice as fast as industry average). REC-1245 is a potentially first-in-class RBM39 degrader for biomarker enriched solid tumors and l...
REC-1245 Case Study
Переглядів 563Місяць тому
REC-1245 - Recursion’s first program to reach clinical studies that derived from our AI-enabled Maps of Biology has received FDA IND clearance for a Phase I/2 clinical trial, progressing from target identification to IND enabling studies in under 18 months. REC-1245 is a potentially first-in-class, potent and selective RBM39 degrader for the treatment of biomarker enriched solid tumors and lymp...
Najat Khan, PhD: From Pharma to TechBio
Переглядів 510Місяць тому
Few people understand the TechBio transformation of pharma like Najat Khan, PhD. Here, 90 days into her new role as Chief R&D and Chief Commercial Officer at Recursion, having previously led the data science and AI team at J&J, she sat down to talk about what motivates her, why she made the leap from pharma to TechBio, and why AI drug discovery and development is ready to deliver. #ai #techbio ...
A Conversation with Yoshua Bengio: How AI Is Driving Powerful Possibilities in Scientific Discovery
Переглядів 2,5 тис.2 місяці тому
Yoshua Bengio, an AI visionary, Turing Award-winner, computer science professor at the University of Montreal and one of our scientific advisors, sat down with Machine Learning Fellow Berton Earnshaw and Chief Technology Officer Ben Mabey to discuss the role of AI in drug discovery. The takeaway: AI will provide transformative brain power to human scientists - and that’s critical for accelerati...
How Recursion Uses Imaging Data to Understand Biology
Переглядів 7792 місяці тому
Imran Haque, SVP of AI and Digital Sciences at Recursion, walks us through the treasure trove of data found in images, explaining how we use algorithms to structure pixels, how we are leading discovery in the field, and the massive advances that have been made in training foundation models to make new predictions of promising therapeutic targets. Some highlights: • Imaging and algorithms can pr...
Inside the Recursion-Exscientia definitive agreement
Переглядів 9013 місяці тому
Chris Gibson and Dave Hallett discuss their shared vision for industry-shifting tech-enabled drug discovery, and how their complementary platforms and approaches can accelerate the discovery of better drugs for patients. Learn more and review important and required disclosure related to this information here: www.globenewswire.com/news-release/2024/08/08/2926843/0/en/Recursion-and-Exscientia-En...
Highlights from Recursion's London Office Opening
Переглядів 5433 місяці тому
Highlights from Recursion's London Office Opening
The Largest Supercomputer in Pharma
Переглядів 1,3 тис.4 місяці тому
The Largest Supercomputer in Pharma
Download Day 2024 - State of Recursion (Chris Gibson, Recursion Co-founder & CEO)
Переглядів 1,9 тис.4 місяці тому
Download Day 2024 - State of Recursion (Chris Gibson, Recursion Co-founder & CEO)
Download Day 2024 - Recursion Operating System (Lina Nilsson, SVP Inception Labs)
Переглядів 1 тис.4 місяці тому
Download Day 2024 - Recursion Operating System (Lina Nilsson, SVP Inception Labs)
Download Day 2024 - Preclinical at Recursion (Laura Schaevitz, SVP and Head of Research)
Переглядів 8764 місяці тому
Download Day 2024 - Preclinical at Recursion (Laura Schaevitz, SVP and Head of Research)
Download Day 2024 - Fireside Chat with Recursion's CMO David Mauro and Dr. Deepak Nijhawan
Переглядів 3634 місяці тому
Download Day 2024 - Fireside Chat with Recursion's CMO David Mauro and Dr. Deepak Nijhawan
Download Day 2024 - Afternoon Convocation (Najat Khan, Recursion Board of Directors)
Переглядів 8804 місяці тому
Download Day 2024 - Afternoon Convocation (Najat Khan, Recursion Board of Directors)
Download Day 2024 - Recursion Partnerships, (Matt Kinn, SVP of BD & Corporate Initiatives)
Переглядів 5124 місяці тому
Download Day 2024 - Recursion Partnerships, (Matt Kinn, SVP of BD & Corporate Initiatives)
Download Day 2024 - Recursion's Clinical Programs (David Mauro, Chief Medical Officer)
Переглядів 4354 місяці тому
Download Day 2024 - Recursion's Clinical Programs (David Mauro, Chief Medical Officer)
Download Day 2024 - Company & Milestones (Michael Secora, Recursion CFO)
Переглядів 3094 місяці тому
Download Day 2024 - Company & Milestones (Michael Secora, Recursion CFO)
Download Day 2024 - Fireside Chat: NVIDIA Founder & CEO Jensen Huang and Recursion's Chris Gibson
Переглядів 33 тис.4 місяці тому
Download Day 2024 - Fireside Chat: NVIDIA Founder & CEO Jensen Huang and Recursion's Chris Gibson
Women in Leadership Video: Kristen Rushton: Full Video
Переглядів 965 місяців тому
Women in Leadership Video: Kristen Rushton: Full Video
Women's Leadership Interview Series: Kristen Rushton
Переглядів 885 місяців тому
Women's Leadership Interview Series: Kristen Rushton
Recursion and Valence Labs Hosts Techbio Panel in London
Переглядів 5716 місяців тому
Recursion and Valence Labs Hosts Techbio Panel in London
Recursion Operating System (OS) Finds Undruggable Targets
Переглядів 6867 місяців тому
Recursion Operating System (OS) Finds Undruggable Targets
Highlight from Women in Leadership Series: Marie Evangelista.
Переглядів 1218 місяців тому
Highlight from Women in Leadership Series: Marie Evangelista.
Women in Leadership Interview: Marie Evangelista
Переглядів 1508 місяців тому
Women in Leadership Interview: Marie Evangelista
Rare Disease Day 2024 at Recursion HQ
Переглядів 2578 місяців тому
Rare Disease Day 2024 at Recursion HQ
Recursionauts Series - The Impact of TechBio
Переглядів 8738 місяців тому
Recursionauts Series - The Impact of TechBio
Recursionauts Series: Mike Genin, Ph.D.
Переглядів 7719 місяців тому
Recursionauts Series: Mike Genin, Ph.D.
the tech Aliagents is developing could be a real game changer for the AI industry
How contact Toronto office?
How do I contact the Toronto office?
No brainer. Semiconductor and AI stocks will dominate 2024. Why I prefer NVIDIA is that they are better placed to maintain long term growth potential, and provide a platform for other AI companies. I have made more than 200% ROI from NVIDIA with the assistance of my fa, I won’t fail to mention. I agree the stock would go higher in the next couple of days.
I bought NVIDIA around October last year because my financial-planner recommended it to me…said the company is selling shovels in a gold rush. It accounted for almost 80% of my market return this year.
That's a great analogy and I love the insight. Professionals could make a really big difference in investing, and I think everyone should have one. There are aspects of market trend that is difficult for the untrained eyes to see. I have made more than 350% through semiconductor stocks under coach by alternative investing. The portfolio comes with perks as well in terms of travel and liquidity.
this is incredible! how can I get your advisor, mind sharing info, if you please?
Her name is Rebecca Nassar Dunne can't divulge much. Most likely, the internet should have her basic info, you can research if you like.
I just curiously searched her up, and I have sent her an email. I hope she gets back to me soon. Thank you
Jensen: Greatest CEO & Founder of All Time
Chris Gibson, you are making $8 million dollars per year. Cut that to $1m so that you don’t have to keep diluting shares to pay your employees and other bills. Get your mind into start up mode until you get paid for molecule.
Chris Gibson, you are making $8 million dollars per year. Cut that to $1m so that you don’t have to keep diluting shares to pay your employees and other bills. Get your mind into start up mode until you get paid for molecule.
Chris Gibson, you are making $8 million dollars per year. Cut that to $1m so that you don’t have to keep diluting shares to pay your employees and other bills. Get your mind into start up mode until you get paid for molecule.
Very exciting!!!
Very excited about this company and will continue to invest ❤
Extraordinary!!!
I think Nvidia should buyout recursion pharmaceutical Inc and invest heavily in the biotechnology industry or should increase its stake well over 50% this, company is exciting there is, lot fortunes to be made hear in next 10 - 15years duration
Meaning in order Tha ai achieve the most important solutions like drug discovery means more gpus purchases from Nvidia
so brilliant and talented Jensen. 🎉
Only if Nvidia could create a new laugh for Martin using generative AI. That would save many many ears worldwide.
Interviewer needs a new laugh and quick.
Million to one just with one picture all information Can me everything ⚛️
Did you have value today ❕
Innovation happiness good mindset great 🆙
My son has FAP. He is 18. No surgery yet. We are waiting for the results on this drug!
Ready to start a new chalange.. I've already applied
This is pretty impressive
used to work in Dr. Li's lab, what a great experience.
Fuckin stupid scam
Wicked smart dude.
Who was here when this stock is 10 dollars a share!! I have 700, wish me luck 🤙
Bro what is up with this interviewer 😂
insightful
What an interesting person, Jensen
1:03
Sort by naturally occurring phytochemical that are not patentable. Now that would be truly impressive
Go Recursion, it's time🎉🎉🎉
Jensen new daddy
Does he always wear that leather jacket? Lol
He is exposed to many models and frontiers in AI, that’s why he facing the constant question why you are here. The next question, how can he glue all the different platforms together as the maga center of AI ?
Ew. wtf is up with the pervy host dude 😂
Simply put, Jensen is a modern day Einstein. Nvidia to $1,500 - for now. : >
What an interviewer, wow.
You're AMAZING!!!!
When I was 16, I only have 1 jean 501. He's ultra-rich. That's truth as he describes it, 40 years since 8086 CPU was born, (1978) and today this is breakthrough with computing power GPU, In the last 40 years, hardware CPU development is way slower than Software development. Case in point, VMWare is a breakthrough in virtualization OS, but CPU/GPU can't not keep up. Now we have a great chance to have a faster GPU/HPC platform, and critically combined with Chat GPT. A new revolution is born today, particularly for scientific research and development and as he describes Data Generation.
It may sound like a silly joke, but the last insight on being able to manage sitting people at a wedding is a solid advice. Exactly what you need to do with agents.
Jensen’s full time job is interviews
ceo number job is sales.
He's doing great
Some companies have tasted the Nvidia rainbow, but now Jensen is ready to scale up and serve even more industries globally. They need a split to cool this inferno.
The humility & good character of Mr Huang is remarkable as a top CEO, wish he can be cloned to lead TSLA.
There is no way of knowing whether his character is good or not without knowing him on a regular personal level. But His public prescence is full of humility and charm. He's great at PR. I'm a fan, by the way, that's why I also know he's a really tough boss. Unless you're a very efficient employee, he's not everyone's cup of tea. Makes Elon look like a soft boss. Otherwise, on a social level, he's pretty cool.
@@kamu747 > Makes Elon look like a soft boss. Wow, really?? Never knew that
@michaeldai1999 Not in a bad way, and I'm not dissing Elon. I'm using Elon for comparison since he has a reputation as a task master. The difference in this case is that Elon from a reputational standpoint is a but inconsiderate towards his expectations of his employees where as as Huang is a considerate boss but an impatient one that has little tolerance for inadequacies and inefficiencies (Which anyone in a position of power obviously wouldn't like inefficiency), he is harsh. And this account comes from him. It's just the nature of the way he goes about it. A sensitive employee wouldn't manage in his environment. Two very different styles of leadership from 2 very capable and successful men.
Very well said they both want to better humanity and are up against all those that will hate all there disruptive ideas and the technology that is coming! Imagine the mentally handicapped defending themselves from intellectuals that take advantage of them because things are not yet equally important! Till they are also going to populate the multiverse!
In one Interview, he is clear abt his 50 direct reports. He insists they gotta be and really are good at their craft and skill. I think Nvidia's success silent pillar must be perfection/precision techniques? Mr.Jensen clearly knows where 'value' is. God bless his Nvidia team🙏🏽
Jensen is brilliant holy shit. Love the mother in law analogy at the end. Solve problems only you can, AI will make it easier to do so.
If that interviewer laughs like a moron again I'm going to punch my screen
NVDA to $1,000
Looking forward to it ! 🎉
Jensen is a visionary, this interviewer on the other hand is a Seth Rogan looking and laughing fool.
You have insulted the interviewer
Jensen, I too am a fan boy. Brilliant communicator.
Wow interviewer aint it. Jensen realizes and just goes off though.
But interviewer has excellent vulgar sound special effects.
I thought the interviewer did an excellent job.
One of his talent is a good in marketing!!!!! More power to you and nvidia, a usa corp.
I think it’s just because Jensen is just way more excited than the interviewer, the audience, and you and me. This is probably why the interviewer doesn’t seem to mind at all. Perhaps biology is one of the area Jensen is most excited about. 😊
Eh it’s alright